Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic capecitabine plus docetaxel as first-line treatment for metastatic breast cancer: phase II
2009-009937-14Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Apr 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and docetaxel in breast cancer, sponsored by European Institute of Oncology. Primary endpoint: Overall response rate. Started Apr 2009; status: completed.
02
Drugs
capecitabinedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-009937-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009937-14.